Back to today’s briefing

Story perspectives

NHS Rejects Costly Alzheimer's Drugs Amid Funding Concerns

6/19/2025

41 3

Summary

Story summary

The NHS has turned down two promising Alzheimer's drugs, citing their exorbitant costs and minimal benefits. NICE warns that funding these treatments could squander taxpayer money and jeopardize other vital services. While campaigners voice their frustration, some dementia specialists back the decision, highlighting the tough choices in healthcare funding.

1 of 1

Story summary

The NHS has turned down two promising Alzheimer's drugs, citing their exorbitant costs and minimal benefits. NICE warns that funding these treatments could squander taxpayer money and jeopardize other vital services. While campaigners voice their frustration, some dementia specialists back the decision, highlighting the tough choices in healthcare funding.